NVIDIA is a strong-buy. What about Intuitive Surgical?

NVIDIA is a strong-buy. What about Intuitive Surgical?

Artificial intelligence is a rapidly developing technology. A lot depends on the companies working on that field. After all, we live in the century of technology. There are lots of stocks out there, and while some of them are truly successful, not all are worth your money.

 

During the pandemic, many companies suffered great losses. Some of them managed to recover or even gained money in the end. Still, before you decide to invest in shares, you should explore the possibilities carefully.

 

As the saying goes, every coin has two sides. While the economic crisis is bad, lowered stock prices give investors the opportunity to buy some shares for a steal. Analysts think that the current economic slowdown will be temporary thanks to the massive stimulus measures from governments.

 

It means that prices will jump again soon. So, it’s an ideal time to add to your portfolio, and some artificial intelligence stocks have great potential. According to experts, NVIDIA and Intuitive Surgical are among them.

 

Why do analysts recommend these two stocks?

 

NVIDIA is one of the best performers in the U.S. stock market. This visual computing company operates in two segments, Tegra Processor and GPU. Its shares have rallied by 77% this year, and by 150% in the last twelve months.

 

Furthermore, NVIDIA traded at $20 at the beginning of 2015, but it now trades at $424.56. The stock’s market capitalization already reached $261.104bn. And it has the potential to gain much more.

 

Intuitive Surgical, on the other hand, met some obstacles during the pandemic crisis. While it reported an adjusted EPS of $1.11 for the second quarter of 2020, earnings plummeted down by 65.8% year-over-year. The stock’s reported revenues are also lower by 22.5% ($852.1 million). Nonetheless, the company has a strong foundation, and experts think that it will rebound soon.

 

Intuitive Surgical designs manufactures and sells da Vinci surgical systems and related instruments in the United States as well as worldwide. The company works with its subsidiaries to achieve all of this. The stock’s market capitalization is worth $80.443bn, and its shares have soared by 15% this year.